2007 Fiscal Year Final Research Report Summary
Development of new vaccine against pathogenic mycobacteria
| Project/Area Number |
17590408
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Bacteriology (including Mycology)
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
MAKINO Masahiko National Institute of Infectious Diseases, Department of Microbiology, Director (60238889)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAEDA Yumi National Institute of Infectious Diseases, Department of Microbiology, Senior Research Scientist (90311399)
YAMAZAKI Toshio National Institute of Infectious Diseases, Department of Microbiology, Senior Research Scientist (20230401)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Keywords | Preventive Medicine / Bacteria / Immunology / Molecular Biology / Animal |
|---|
| Research Abstract |
The activation of T lymphocytes inhibits the intracellular and intercellular multiplication of Mycobacterium leprae. Therefore, leprosy provides a useful model for the development of vaccine against pathogenic mycobacterial infection. First of all, we identified major membrane protein (MMP)-II as one of the immunodominant antigens of M. leprae. The recombinant MMP-II protein recognized the TLR2 molecules expressed on the surface of antigen-presenting cells and strongly activated both dendritic cells (DC) and macrophages. The DC pulsed with MMP-II activated autologous naive CD4^+ T cells and naive CD8^+ T cells obtained from healthy individuals. Further, memory type T lymphocytes obtained from paucibacillary (PB) leprosy patients responded to MMP-II and produced higher amount of IFN-γ than those from healthy individuals. These results suggest that T cells in PB leprosy are primed with MMP-II in vivo. In addition, macrophages produced from monocytes in the presence of GM-CSF and infected
… More
with M. leprae activated T lymphocytes. Then, we produced a recombinant BCG (BCG-SM) that secretes MMP-II intracytosollicaly in host cells. DC infected with BCG-SM more strongly activated autologous naive CD4^+ T lymphocytes to produce IFN-γ than those infected with vector control BCG. Further, while vector control BCG did not activate naive CD8^+ T lymphocytes, BCG-SM induced a significant production of IFN-γ from naive CD8^+ T lymphocytes. BCG-SM also induced GM-CSF production by macrophages and, through the GM-CSF production, BCG-SM-infected macrophages activated CD4^+ T lymphocytes. C57BL/6 mice infected with BCG-SM 13 weeks before, efficiently produced memory T lymphocytes which react to MMP-II in vitro. Finally we intradermally vaccinated C57BL/6 mice with either vector control BCG or BCG-SM and, four weeks later, we challenged to the vaccinated mice with M. leprae. The BCG-SM vaccination was more efficiently inhibited the multiplication of M leprae in vivo than vector control BCG. Taken together, we successfully produced more efficient BCG than parent BCG in inhibiting M. leprae growth. Less
|
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] らい菌膜免疫調整性蛋白の同定2005
Author(s)
前田百美,向井 徹,山下康子,牧野正彦.
Organizer
第78回日本ハンセン病学会総会・学術大会
Place of Presentation
青森
Year and Date
20050500
Description
「研究成果報告書概要(和文)」より
-
